Last $3.40 USD
Change Today +0.02 / 0.59%
Volume 224.2K
PSTI On Other Exchanges
Tel Aviv
As of 8:10 PM 04/15/14 All times are local (Market data is delayed by at least 15 minutes).

pluristem therapeutics inc (PSTI) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/21/14 - $4.63
52 Week Low
06/4/13 - $2.47
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

pluristem therapeutics inc (PSTI) Related Businessweek News

No Related Businessweek News Found

pluristem therapeutics inc (PSTI) Details

Pluristem Therapeutics Inc., through its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company. It is engaged in the research, development, and commercialization of standardized cell therapy products and related technologies for the treatment of local and systemic diseases. The company’s PLX (PLacental eXpanded) cells function as a drug delivery platform that releases a number of therapeutic proteins in response to various local and systemic inflammatory and ischemic signals generated by the patient. PLX cells are grown using proprietary three-dimensional micro-environment technology that produces an off-the-shelf products. It develops PLX-PAD cells, which are in Phase-II clinical trials for use in treatment of peripheral and cardiovascular, orthopedic, and pulmonary diseases; and PLX-RAD cells are used for acute radiation syndrome treatment. Pluristem Therapeutics Inc. is also involved in the development and commercialization of a PLX cell-based product for the treatment of pulmonary artery hypertension through its license agreement with the United Therapeutics Corporation; and commercialization agreement with CHA Bio&Diostech for conducting clinical trials and commercialization of PLX-PAD products in South Korea. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.

142 Employees
Last Reported Date: 09/11/13
Founded in 2001

pluristem therapeutics inc (PSTI) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $544.2K
President and Chief Operating Officer
Total Annual Compensation: $326.3K
Compensation as of Fiscal Year 2013.

pluristem therapeutics inc (PSTI) Key Developments

Pluristem Therapeutics, Inc. Presents at 13th Annual Needham Healthcare Conference, Apr-09-2014 10:00 AM

Pluristem Therapeutics, Inc. Presents at 13th Annual Needham Healthcare Conference, Apr-09-2014 10:00 AM. Venue: The Westin Grand Central Hotel, New York, New York, United States.

Pluristem Therapeutics, Inc. Presents at Barclays Capital 2014 Global Healthcare Conference, Mar-11-2014 08:30 AM

Pluristem Therapeutics, Inc. Presents at Barclays Capital 2014 Global Healthcare Conference, Mar-11-2014 08:30 AM. Venue: Loews Miami Beach Hotel, Miami, Florida, United States. Speakers: Boaz Gur-Lavie, Chief Financial Officer, Vice President of Finance and Secretary.

US FDA Approves Pluristem's Commercial Scale Cell Manufacturing Process

Pluristem Therapeutics, Inc. announced that the United States Food and Drug Administration (FDA) has reviewed Pluristem's comparability studies of its PLacental eXpanded (PLX) cell products and granted approval for the Company to manufacture these products in its new commercial-scale cell manufacturing facility. At its new GMP manufacturing facility, Pluristem has implemented its proprietary, fully automated 3D cell expansion manufacturing platform that uses its patented high-throughput culturing technologies, 3D bioreactors, and downstream equipment. Pluristem's facility has the ability to efficiently produce approximately 150,000 doses of PLX cells annually, with batch-to-batch consistency, which potentially translates into significant economic value.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PSTI:US $3.40 USD +0.02

PSTI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Athersys Inc $2.64 USD -0.06
Cytomedix Inc $0.54 USD +0.01
Cytori Therapeutics Inc $2.25 USD -0.03
InspireMD Inc $2.39 USD -0.108
NeoStem Inc $6.43 USD -0.36
View Industry Companies

Industry Analysis


Industry Average

Valuation PSTI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 434.0x
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 360.1x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PLURISTEM THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at